COX-2-Selective Inhibitors to Treat Asprin-Insensitive Thromboxane Biosynthesis: A Randomised Cross-Over Trial

    Project Details

    StatusFinished
    Effective start/end date1/01/0431/12/05

    Funding

    • National Heart Foundation